Vivodyne's human tissue factory could change drug testing, Endpoints 11 winner says

The Endpoints 11 awards recognized Vivodyne as its 2026 winner, citing the company’s work building human tissue systems intended to replace portions of animal and cell-culture testing in early drug development. According to Endpoints News, Vivodyne’s platform grows functional human tissue constructs that can be exposed to candidate compounds, generating data on efficacy and toxicity before a drug reaches clinical trials.

The report frames the technology as addressing a persistent translation gap in pharmaceutical research, the recurring failure of results from animal models and simplified cell cultures to predict how a drug behaves in human patients. By testing directly on lab-grown human tissue, the company argues it can surface safety and efficacy signals earlier and more reliably, potentially reducing the number of compounds that fail in costly later-stage human trials.

Endpoints News did not report specific efficacy figures or named partner companies in the excerpt provided, nor a timeline for broader industry adoption. The recognition places Vivodyne among a small group of tissue-engineering firms pursuing alternatives to conventional animal testing, a category that has drawn increasing regulatory and industry attention as agencies signal openness to non-animal testing methods in review pathways.

No further details on funding, prior publications, or specific tissue types produced were included in the cited coverage.